Articles from Organigram Holdings Inc.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its first quarter fiscal 2025 ended December 31, 2024, on Tuesday, February 11, 2025, prior to market open.

This earnings release replaces the previously filed earnings release on December 18, 2024 to correct errors in the outstanding share data tables under the heading “CAPITAL STRUCTURE.” No other changes are being made. The Company is also refiling its Management’s Discussion and Analysis for the twelve months ended September 30, 2024 to correct corresponding errors in the outstanding share data table, which corrections will also apply to the MD&A included in the Company’s Annual Report filed on December 18, 2024.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its fourth quarter and fiscal 2024 ended September 30, 2024, on Wednesday, December 18, 2024, prior to market open.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce the acquisition of 100% of the issued and outstanding shares of Motif Labs Ltd. (“Motif”), for upfront consideration of $90 million, consisting of $50 million in cash and $40 million of Organigram common shares priced based on the 30 day trading VWAP of $2.3210 on the Toronto Stock Exchange (“TSX”). In addition, Motif shareholders will be entitled to receive additional contingent consideration of $10 million payable in Organigram common shares (“Contingent Consideration”), conditional on Organigram achieving a price per share exceeding $3.2203 per share, based on the rolling 30-trading day VWAP on the TSX, within 12 months of the date of the transaction. The Contingent Consideration shall be priced at of $3.22031 per share.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is thrilled to finally launch Edison Sonics gummies, Organigram’s inaugural product powered by FAST™, the Company’s groundbreaking nanoemulsion technology and a first-to-market innovation.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today that on August 30, 2024, the Company closed the second of three tranches (the “Second Tranche”) of the previously announced C$124,559,674 follow-on strategic equity investment (the “Investment”) by BT DE Investments Inc. (the “Investor”), a wholly owned subsidiary of British American Tobacco plc (“BAT”). Pursuant to the Second Tranche closing, the Investor acquired 4,429,740 common shares (the “Common Shares”) and 8,463,435 Class A preferred shares (the “Preferred Shares” and together with the Common Shares, the “Shares”) of the Company at a price of C$3.2203 per share (the “Per Share Price”) for gross proceeds of USD$30,821,684.69 (equal to C$41,519,891)1. The remaining 12,893,175 Shares subscribed for are due to be issued at the Per Share Price in the final tranche on or around February 28, 2025 (the “Third Tranche”).

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the third quarter ended June 30, 2024 (“Q3 Fiscal 2024”).

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), a leading licensed producer of cannabis, is pleased to unveil the preliminary results of its landmark clinical pharmacokinetic (PK) study conducted via the Product Development Collaboration (PDC) on its latest innovation, nanoemulsion technology. This patent-pending technology, branded FAST™ (Fast Acting Soluble Technology), will be the first innovation to be commercialized by Organigram leveraging the output of the PDC*, a “Center of Excellence” established to focus on developing next-generation cannabis products.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its third quarter fiscal 2024 ended June 30, 2024, on Tuesday, August 13, 2024, prior to market open.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced the appointment of Craig Harris to the Organigram Board of Directors effective today. Craig brings over 20 years of experience as a commercial lawyer, with a background in private practice and legal and regulatory engagement roles for various corporations. He is currently the Assistant General Counsel – Corporate & Commercial Legal at British American Tobacco plc (BAT).

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that it has completed an early partial funding of its final third tranche investment into Phylos Bioscience Inc. (“Phylos”), a U.S. cannabis genetics company and provider of production ready seeds, with the remaining portion of the final tranche to be funded upon completion of the newly expanded final milestone.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce its first significant strategic investment aimed at expanding its presence in the European cannabis market. Using proceeds from its Jupiter strategic investment pool, the Company has agreed to invest €14 million (~ C$21 million) initially comprised of €11.5 million via an unsecured convertible note and €2.5 million to purchase equity interests from existing Sanity Group founders and shareholders providing the Company with a minority stake in Berlin-based cannabis company Sanity Group GmbH (“Sanity” or “Sanity Group”). In addition, the Company may advance another €3 million (~ C$4.5 million) as a second tranche of the unsecured convertible note for future opportunities to be pursued by Sanity subject to the satisfaction of certain conditions.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce its second international medical cannabis customer in the UK, Avida Medical, a full-service medical cannabis and specials medicines manufacturing business.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the second quarter ended March 31, 2024 (“Q2 Fiscal 2024”).

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its second quarter fiscal 2024 ended March 31, 2024, on Tuesday, May 14, 2024, prior to market open.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce it has been recognized on the 2024 Report on Business ‘Women Lead Here’ list for gender diversity. Fifty percent of the Company’s executive leadership team, including its CEO, are women.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, celebrates a monumental achievement as its SHRED brand surpasses the $200 million mark in yearly retail sales.1

Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI; NASDAQ: OGI) announces today the closing of its previously announced underwritten public offering of units of the Company (the “Units”) for total gross proceeds of C$28,750,230 (the “Offering”). The Company sold 8,901,000 Units at a price of C$3.23 per Unit, which included 1,161,000 Units sold pursuant to the exercise in full of the Underwriters’ over-allotment option.

Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI; NASDAQ: OGI), announces today that, in connection with its previously announced overnight marketed public offering of units of the Company (the “Units”), it has entered into an underwriting agreement with ATB Securities Inc., as lead underwriter, on behalf of itself and a syndicate of underwriters to sell 7,740,000 Units at a price of C$3.23 per Unit (the “Offering Price”) for total gross proceeds of approximately C$25 million (the “Offering”).

Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI; NASDAQ: OGI), announces today an overnight marketed public offering of units of the Company (the “Units”) for total gross proceeds of approximately C$25 million (the “Offering”). The Offering is expected to be completed pursuant to an underwriting agreement to be entered into between the Company and ATB Securities Inc., as lead underwriter, on behalf of itself and a syndicate of underwriters including A.G.P. Canada Investments ULC. The Offering will be made in the United States through the lead underwriter's U.S. affiliate, ATB Capital Markets USA Inc.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”) is pleased to announce a US $2 million minority investment in Steady State LLC (d/b/a Open Book Extracts) (“OBX”) in the form of a convertible note.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”) enthusiastically supports the Standing Committee on Finance’s recent recommendation on the Excise Duty framework.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the first quarter ended December 31, 2023 (“Q1 Fiscal 2024”).

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its first quarter fiscal 2024 ended December 31, 2023, on Tuesday, February 13, 2024, prior to market open.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis today announced that it has sent its first shipment of bulk dried flower to the medical division of German cannabis company, Sanity Group, a health and sciences organization dedicated to the medical applications of cannabinoids. Organigram is pleased to complete its first shipment to Germany, one of the world’s largest and growing medical markets, as part of its multi-year agreement with Sanity Group.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today that it has closed the first of three tranches of the previously announced C$124,559,674 follow-on strategic equity investment (the “Investment”) by BT DE Investments Inc. (the “Investor”), a wholly owned subsidiary of British American Tobacco plc (“BAT”). Pursuant to the first tranche closing, the Investor acquired 12,893,175 common shares of the Company at a price of C$3.2203 per share (the “Per Share Price”) for gross proceeds of C$41,519,891. The remaining 25,786,350 shares subscribed for shall be issued at the Per Share Price in two further equal tranches on or around August 30, 2024 and February 28, 2025.

Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI) (NASDAQOGI), announced the appointment of Karina Gehring to the Organigram Board of Directors at the Company’s annual general and special meeting held on January 18, 2024.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today that it has mailed and filed a management information circular (the “Circular”) and related materials (the “Meeting Materials”) for its annual and special meeting (the “Meeting”) of the holders of its common shares (the “Shareholders”) to be held on January 18, 2024. In addition to routine annual business to be conducted (including the election of directors and the appointment of an auditor), Shareholders at the Meeting will be asked to approve the previously announced proposed C$124.6 million follow-on strategic equity investment in the Company (the “Investment”) from BT DE Investments Inc. (the “Investor”), a wholly owned subsidiary of British American Tobacco plc (“BAT”). The Investment is to be completed in three tranches, each subject to the satisfaction of certain closing conditions, which include (among other things), clearance under the Competition Act (satisfied on November 23, 2023), applicable stock exchange approval (TSX conditional approval of the Investment received on December 19, 2023), and the requisite approval of the Shareholders at the Meeting.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the fourth quarter and thirteen months ended September 30, 2023 (“Q4 Fiscal 2023” or "Fiscal 2023").

Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI) (NASDAQOGI) is pleased to announce that Greg Guyatt CPA, CA, formerly of Phoena Holdings Inc. (“Phoena”), has been appointed to the role of Chief Financial Officer effective January 8, 2024. Mr. Guyatt will lead Organigram’s Finance and IT divisions and will report directly to Beena Goldenberg, Organigram’s Chief Executive Officer.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its fourth quarter and fiscal 2023 ended September 30, 2023, on Tuesday, December 19, 2023, before market open.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), the parent company of a leading licensed producer of cannabis (the “Company” or “Organigram”), is thrilled to announce it has won KIND Magazine’s (“KIND”) Innovation of the Year award for its revolutionary SHRED X Rip-Strips Hash. This is the second time Organigram has won this coveted award, having previously won for the Company’s patented Edison JOLTS ingestible extract product.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that Phylos Bioscience Inc. (“Phylos”), a U.S. cannabis genetics company and provider of production ready seeds, has achieved the first milestone under the loan agreement entered into in May 2023 (the “Loan Agreement”) and has closed the second tranche under the Loan Agreement with Organigram advancing US$2.75 million to Phylos. This second tranche follows the initial tranche of US$3.25 million advanced in May 2023 for a total of US$6 million in senior secured convertible loans (“Convertible Loans”) currently outstanding.

The Board of Directors (the “Board”) of Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI) (NASDAQOGI) today announced that Derrick West has informed Organigram that he will transition away from his role as Chief Financial Officer (“CFO”) in order to take time to focus on his health and recovery following surgery later this month.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce a C$124.6 million follow-on strategic equity investment from BT DE Investments Inc., (the “Investment”), a wholly-owned subsidiary of BAT (LSE: BATS and NYSE: BTI) (“BAT”), a leading, multi-category consumer goods business with a purpose to build A Better Tomorrow.™

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to provide a corporate update.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licenced producer of cannabis, announced today that it has obtained a receipt for a final short form base shelf prospectus (the “Base Shelf Prospectus”) filed with the securities commissions in each of the provinces and territories of Canada. A corresponding shelf registration statement on Form F-10 (the “Registration Statement”) has been filed with the United States Securities and Exchange Commission (SEC File No. 333-274686) but is not yet effective.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licenced producer of cannabis, announced today that it has filed a preliminary short form base shelf prospectus (the “Base Shelf Prospectus”) with the securities commissions in each of the provinces and territories of Canada. A corresponding shelf registration statement on Form F-10 (the “Registration Statement”) has been filed with the United States Securities and Exchange Commission but is not yet effective.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announces today that Ms. Caroline Ferland has resigned from the Board of Directors (“the Board”) effective immediately. Ms. Ferland was a board member nominee appointed by BAT.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to launch its first range of whole-flower derived THCV products through the Company’s popular SHRED and newly re-launched Trailblazer brands.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce the relaunch of one of Canada’s best known cannabis brands, Trailblazer, exemplifying the Company’s commitment to keeping consumer insights at the heart of its brand and product development strategy. More than a year in the making, Trailblazer’s modernized brand identity and revitalized product lineup represent a significant opportunity to connect with a large and important consumer segment whose needs were previously unmet by the Organigram brand portfolio. Featuring THCV gummies, CBG infused pre-rolls and a high-potency 1x0.5g pre-roll, Trailblazer will re-enter the market with a range of differentiated offerings.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce today that it has expanded its global footprint by entering into a supply agreement (“the Agreement”) to provide dried Medical Cannabis flower to 4C LABS, a rapidly scaling healthcare, technology, and pharmaceutical company focused on virtual prescribing, pharmaceutical distribution, and clinical development of cannabis-based products for human health in the United Kingdom.

Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI; NASDAQ: OGI), announced today that the Federal Court of Canada (the “Court”) has granted Organigram’s application for judicial review of a decision of Health Canada determining that the Edison Jolts lozenges (the “Products”) are to be classified as edible cannabis. The Court found there was a breach of procedural fairness by Health Canada. The matter is being remitted back to Health Canada for redetermination taking the Court’s reasons into consideration.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce the launch of its new tube-style pre-rolls, SHRED Dartz and Holy Smokes. These tube-style pre-rolls mark the inception of 0.4g pre-rolls for Organigram, crafted using the state-of-the-art, high-speed Cantos tube-style rolling machine, complemented by cutting-edge packaging capabilities. Organigram today, is one of a small number of licensed producers (LPs) in Canada that possess the equipment and expertise to manufacture this sophisticated tube-style pre-roll format.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the third quarter ended May 31, 2023 (“Q3 Fiscal 2023”). All financial information in this press release is expressed in thousands of Canadian dollars ("$"), except for references to $ millions.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its third quarter fiscal 2023 ended May 31, 2023, on Thursday, July 13, 2023, after market close.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce the launch of SHRED X Heavies, a line of innovative infused pre-rolls. Infused with both diamonds and distillate, this is the first infused pre-roll offering from Organigram that will have a potency of over 40%. The infusion of botanical terpenes further enhances the natural terpene profiles of the blends, taking them to new and delicious heights.

Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI; NASDAQ: OGI) announced today that its Board has approved the consolidation of the Company’s issued and outstanding common shares at a consolidation ratio of four (4) pre-consolidation common shares for every post-consolidation common share (the “Share Consolidation”). The Share Consolidation is being implemented to ensure the Company continues to comply with Nasdaq listing requirements, reduce volatility and to enhance the marketability of the common shares to institutional investors.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that it has reached agreement with Phylos Bioscience Inc. (“Phylos”), a U.S. cannabis genetics company and provider of production ready seeds, based in Portland, Oregon, to initiate a wide-ranging technical and commercial relationship in Canada. This innovation relationship is expected to further support Organigram’s industry leading cultivation efforts in Canada with patent-pending foundational technologies and genetics. In the future, subject to receipt of any required approvals and permits, Organigram intends to export THCV products to select legal international markets.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce today that it has entered into a supply agreement (“the Agreement”) for dried flower with the medical division of German cannabis company Sanity Group, a health and life sciences company based in Berlin, Germany, dedicated to the medical applications of cannabinoids. Through exports from its flagship state-of-the-art cultivation facility in Moncton, Organigram already services medical patients in Israel and Australia, and will now add Germany to its growing list of international markets.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that its wholly-owned subsidiary, The Edibles and Infusions Corporation (“EIC”) has met certain of the remaining earnout milestones that formed part of the terms of its acquisition in April, 2021.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the second quarter ended February 28, 2023 (“Q2 Fiscal 2023”). All financial information in this press release is expressed in thousands of Canadian dollars ("$"), except for references to $ millions.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its second quarter fiscal 2023 ended February 28, 2023, on Tuesday, April 11, 2023, after market close.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it has entered into a product purchase agreement (“Purchase Agreement”) with Green Tank Technologies Corp. (“Greentank”) a leading vaporization technology company and a subscription agreement (“Subscription Agreement”) with Greentank’s parent company, Weekend Holdings Corp (“Holdings”).

Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI; NASDAQ: OGI), announced that BAT has designated Ms. Caroline Ferland as a nominee to Organigram’s board of directors (the “Board”). Caroline Ferland is a lawyer with extensive international experience assisting multinational companies to operate with confidence and integrity in highly regulated and high-risk environments. As the first Group Head of Business Conduct and Compliance for BAT, Caroline led the design and implementation of BAT’s global compliance and ethics programme (BAT operates in more than 150 jurisdictions across the world). Caroline is also experienced in managing strategic litigation and regulatory investigations. She was awarded the Advocatus Emeritus (Ad.E) recognition by the Quebec Bar in 2014. Previously, she chaired the Board of Directors of the Quebec Branch of the Canadian Bar Association, and of the Centre d’accès à l’information juridique. She was also a Director of other Boards, such as the Fondation Marie-Vincent, the Barreau du Québec and the Barreau de Montréal. Ms. Ferland is a Chartered Director (C.Dir) and recognized Administrateur de sociétés certifié (ASC). Caroline holds a BA in Economics from Université de Sherbrooke, as well as a B.C.L. and an LL.B Law from McGill University. Ms. Ferland’s appointment brings the Company’s total number of directors to ten.

Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI; NASDAQ: OGI), announced that it has received notification from Health Canada that Health Canada has determined that certain Jolts lozenge products in their 100 mg THC per package format (the “Products”) have been improperly classified as an “extract” rather than an “edible” under the Cannabis Regulations. The Company launched the Products in August 2021 following significant research, development and regulatory work. The Company remains of the view that the patent pending Products are properly classified as cannabis extracts and compliant with the Cannabis Regulations, and is assessing its options with its legal advisors. At present, the Company has paused production of the Products in the current packaging format, pending resolution of the matter. According to Health Canada’s notification, the Company can continue to sell and distribute inventory of the Products until May 31, 2023.

Organigram Holdings Inc. (“Organigram” or the “Corporation”) (TSX: OGI) (NASDAQOGI) announced today the results of voting at its annual general and special meeting of shareholders held on February 28, 2023 (the “Meeting”).

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce the launch of SHRED X Rip-Strip Hash, a first-of-its-kind innovation in the Canadian cannabis industry. This botanical terpene-infused hash is unlike any other on the market – with 10 pre-cut strips of hash available in a 2g format. This product is a new ultra-convenient hash offering from SHRED that is available in the legendary Tropic Thunder and new Blueberry Blaster flavour profiles.

Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI; NASDAQ: OGI), today announced that it received notification (the “Notification”) from The Nasdaq Stock Market LLC (“NASDAQ”) that it is not in compliance with the minimum bid price requirement in NASDAQ Listing Rule 5450(a)(1) for continued listing on the NASDAQ Global Select Market, since the closing bid price for the Company’s common shares listed on NASDAQ was below US$1.00 for 30 consecutive trading days. NASDAQ Listing Rule 5450(a)(1) requires the common shares to maintain a minimum bid price of US$1.00 per share (the “Minimum Bid Requirement”), and NASDAQ Listing Rule 5810(c)(3)(A) provides that failure to meet such requirement exists if the deficiency continues for a period of 30 consecutive business days.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the first quarter ended November 30, 2022 (“Q1 Fiscal 2023”). All financial information in this press release is expressed in thousands of Canadian dollars ("$"), except for references to $ millions.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its first quarter fiscal 2023 ended November 30, 2022, on Thursday, January 12, 2023, before market open.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), the parent company of a leading licensed producer of cannabis (the “Company” or “Organigram”), is pleased to announce it has won KIND Magazine’s (“KIND”) Cannabis Company of the Year award. Considered KIND’s marquee award, Cannabis Company of the Year is presented to the licensed producer that the KIND editorial team believes demonstrates the best combination of people, purpose and product in a given year.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the fourth quarter and year ended August 31, 2022 (“Q4 Fiscal 2022” or "Fiscal 2022").

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce the launch of HOLY MOUNTAIN, the Company’s newest value brand featuring an initial lineup of dried flower strains and entering the market with value pressed hash. With the introduction of HOLY MOUNTAIN, Organigram will now offer value-priced flower in an expanded range of sizes, starting with 3.5g offerings at launch and additional sized formats expected soon after.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its annual and fourth quarter fiscal 2022 ended August 31, 2022 on Monday, November 28, 2022, after market close.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), ( “Organigram”) a leading Canadian licensed producer of cannabis and Canndoc Ltd. (“Canndoc”), a subsidiary of InterCure Ltd. NASDAQ: INCRNASDAQINCR)

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the third quarter ended May 31, 2022 (“Q3 Fiscal 2022”).

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its third quarter 2022 ended May 31, 2022 on Thursday, July 14, 2022 before market open.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), and its subsidiary Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis in Canada, has reached a proposed settlement (“Settlement”) in a previously disclosed class action related to medical cannabis that was voluntarily recalled in December 2016 and January 2017 (“Class Action”). The Supreme Court of Nova Scotia (the “Court”) approved notice of Settlement will be sent to class members beginning on June 24, 2022.

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the second quarter ended February 28, 2022 (“Q2 Fiscal 2022”).

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its second quarter 2022 ended February 28, 2022 on Tuesday, April 12, 2022 before market open.

Organigram Holdings Inc. (TSX: OGI and NASDAQ: OGI), the parent company of Organigram Inc. (collectively “Organigram” or the “Company”), a leading licensed producer of cannabis, provided a corporate update today.

Organigram Holdings Inc. (TSX: OGI and NASDAQ: OGI), the parent company of Organigram Inc. (collectively “Organigram” or the “Company”), a leading licensed producer of cannabis, is pleased to announce the launch of its social impact strategy ‘Organigram Operating for Good’ with the purpose of ‘Building healthy communities where we live and work.’ As part of this strategy the Company has committed to giving back by joining the Pledge 1% Movement. Organigram has pledged ‘1% of Time’ which means the Company will be donating 1% of its employees’ time to local volunteer programs. Organigram employees across Canada will be encouraged to support causes and events in the communities in which they live and work either through group or individual volunteering opportunities.

Organigram Holdings Inc. (“Organigram” or the “Corporation”) (TSX: OGI) (NASDAQOGI) announced today the results of voting at its annual meeting of shareholders held on February 23, 2022 (the “Meeting”).

Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the first quarter ended November 30, 2021 (“Q1 Fiscal 2022”).